2013 Fiscal Year Final Research Report
Enhanced antitumor efficacy of telomerase-selective oncolytic adenobiral agent OBP-301 with chemotherapy in osteosarcoma.
| Project/Area Number |
24890132
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Orthopaedic surgery
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2012-08-31 – 2014-03-31
|
| Keywords | テロメラーゼ / ウイルス療法 / 骨肉腫 |
|---|
| Research Abstract |
We investigated the chemosensitizing effect of a telomerase-specific replication-competent oncolytic adenovirus, OBP-301, in human osteosarcoma cells. OBP-301 infection enhanced the cytotoxic effect of chemotherapy and increased chemotherapy-mediated apoptosis through downregulation of Mcl-1 expression. Combination therapy significantly suppressed tumor growth in a subcutaneous xenograft model. These results suggest that combination therapy provides a novel therapeutic strategy for human osteosarcomas.
|
